|1.||Thompson, Timothy C: 1 article (11/2008)|
|2.||Floryk, Daniel: 1 article (11/2008)|
|3.||Zhang, Yanping: 1 article (01/2008)|
|4.||Huang, Min: 1 article (01/2008)|
|5.||Mitchell, Beverly: 1 article (01/2008)|
|6.||Ji, Yanshan: 1 article (01/2008)|
|7.||Itahana, Koji: 1 article (01/2008)|
|8.||Chen, Liqiang: 1 article (07/2007)|
|9.||Pankiewicz, Krzysztof W: 1 article (07/2007)|
|1.||Prostatic Neoplasms (Prostate Cancer)
11/15/2008 - "In this study, we investigated the effects of IMPDH inhibitor AVN944 on LNCaP, CWR22Rv1, DU145 and PC-3 human prostate cancer cells. "
11/15/2008 - "AVN944 is a novel, promising therapeutic agent that might be combined with other agents for treatment of human prostate cancer."
11/15/2008 - "In summary, AVN944 inhibited the growth of human prostate cancer cells by inducing cell cycle arrest, cell death as well as differentiation. "
11/15/2008 - "AVN944 inhibited proliferation of these 4 prostate cancer cell lines and was associated with cell cycle G1 arrest of LNCaP cells and S-phase block of androgen-independent CWR22Rv1, DU145 and PC-3 cells. "
11/15/2008 - "AVN944 induced expression of p53-target proteins Bok, Bax and Noxa in androgen-responsive cell lines and suppressed expression of survivin in prostate cancer cells regardless of their androgen sensitivity. "
|2.||Hematologic Neoplasms (Hematological Malignancy)
01/01/2008 - "The ability of AVN-944 to induce apoptosis in a number of leukemic cell lines supports its potential utility in the treatment of hematologic malignancies."
07/01/2007 - "Related compounds such as mycophenolic adenine dinucleotides, along with second-generation analogs, are undergoing preclinical evaluation, while another inhibitor of IMPDH, AVN-944, is currently in phase I clinical trials to investigate the treatment of hematological malignancies. "
|1.||Proteins (Proteins, Gene)